MedTrace Logo

Isolation of Circulating Pulmonary Cells in COPD and Its Relationship With Clinical Relevant Outcomes (IbICEnCa)

NCT03591978 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-04-03

No results posted yet for this study

Summary

We have demonstrated for the very first time that it is possible to isolate CPCs (circulating pulmonary cells) in patients with COPD in a sample of 17 patients (with a recovery rate of nearly 40%) and none of 10 healthy, non- smokers controls with a patented method \[provisional Spanish Patent Application (P201730724)\], based on liquid biopsy methodology (Romero Palacios et at, submitted 2017), showing that patients with COPD and isolation of CPCs have a more severe disease (expressed as higher BODEx index) and a trend towards a higher rate of decline of lung function as well as an increased rate of exacerbations, suggesting that CPCs isolation could be of value as a diagnostic and prognostic tool identifying patients with more active diseases. However, due to the small sample, no definitive conclusions could be made. Moreover, as there were no healthy smokers included in this study, we couldn´t evaluate if CPCs could be isolated in this type of population.

The fact that CPCs could be isolated in a group of patients with COPD and its relationship with greater severity suggests that this could be a marker of progression of the disease and could detect those patients more likely to benefit from newer antiinflamatory therapies(17)

Conditions

  • COPD
  • COPD Exacerbation
  • COPD, Severe Early-Onset

Interventions

DIAGNOSTIC_TEST

Isolation of Circulating Pulmonary Cells in peripheral blood

Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)

Sponsors & Collaborators

  • Hospital de Alta Resolucion de Loja. Agencia Sanitaria Hospital de Poniente

    collaborator OTHER

  • Junta de Andalucia

    collaborator OTHER_GOV

  • Universidad de Granada

    lead OTHER

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-11-01
Completion
2021-05-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03591978 on ClinicalTrials.gov